[HTML][HTML] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
R Carraro, A Harper, M Kunesova, MEJ Lean… - International journal of …, 2012 - nature.com
Objective: Having demonstrated short-term weight loss with liraglutide in this group of obese
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
A Astrup, R Carraro, N Finer, A Harper… - International Journal of …, 2012 - go.gale.com
Objective: Having demonstrated short-term weight loss with liraglutide in this group of obese
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …
[PDF][PDF] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
A Astrup, R Carraro, N Finer, A Harper… - … Journal of Obesity, 2012 - researchgate.net
Objective: Having demonstrated short-term weight loss with liraglutide in this group of obese
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …
[PDF][PDF] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
A Astrup, R Carraro, N Finer, A Harper… - … Journal of Obesity, 2012 - cyberleninka.org
Objective: Having demonstrated short-term weight loss with liraglutide in this group of obese
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
A Astrup, R Carraro, N Finer, A Harper… - … Journal of Obesity …, 2011 - europepmc.org
Objective Having demonstrated short-term weight loss with liraglutide in this group of obese
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …
[HTML][HTML] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
A Astrup, R Carraro, N Finer, A Harper… - … Journal of Obesity …, 2012 - ncbi.nlm.nih.gov
Objective: Having demonstrated short-term weight loss with liraglutide in this group of obese
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …
[引用][C] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
A Astrup, R Carraro, N Finer… - … Journal of Obesity, 2012 - researchportal.helsinki.fi
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1
analog, liraglutide — University of Helsinki Skip to main navigation Skip to search Skip to main …
analog, liraglutide — University of Helsinki Skip to main navigation Skip to search Skip to main …
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
A Astrup, R Carraro, N Finer, A Harper, M Kunesova… - 2012 - cabidigitallibrary.org
Objective: Having demonstrated short-term weight loss with liraglutide in this group of obese
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
A Astrup, R Carraro, N Finer, DA Harper… - International Journal of …, 2012 - pure.au.dk
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1
analog, liraglutide — Aarhus University Skip to main navigation Skip to search Skip to main …
analog, liraglutide — Aarhus University Skip to main navigation Skip to search Skip to main …
[PDF][PDF] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
A Astrup, R Carraro, N Finer, A Harper… - International Journal of …, 2012 - academia.edu
Objective: Having demonstrated short-term weight loss with liraglutide in this group of obese
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …